Amicus out-licenses Fabry's candidate to GSK

Amicus Therapeutics Inc. (NASDAQ:FOLD) granted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to Fabry's disease candidate Amigal migalastat. The small molecule that enhances alph...